{"success":true,"data":{"pressRelease":{"id":"25290","rtpr_id":"nGNX3T6lCv","ticker":"ASG","exchange":"","all_tickers":["ASG"],"title":"Aurora Spine Announces Issuance of Fourth U.S. Patent Covering DEXA Technology® Bone Density-Matched Implants","author":"Globe Newswire","published_at":"2026-05-07T11:15:00.111Z","article_body":"CARLSBAD, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aurora Spine Corporation\n(“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader\nin the development of groundbreaking medical devices for spinal surgery, today\nannounced the issuance of its fourth U.S. patent related to Aurora’s\nproprietary DEXA Technology® platform.\n\nThe newly issued patent, U.S. Patent No. 12,605,252 B2, titled “Bone Density\nScan Result-Matched Orthopedic Implants and Methods of Use,” was issued on\nApril 21, 2026, and further strengthens Aurora Spine’s intellectual property\nportfolio surrounding patient-specific, bone density-matched implant selection\nand use.\n\nThe patented technology describes methods for obtaining a patient’s bone\ndensity information, including a DEXA T-score or bone density measurement,\nselecting an implant having a density level matched to the patient’s native\nbone at the implantation site, and implanting the selected device. The patent\nfurther supports Aurora’s broader DEXA Technology platform, which is\ndesigned to provide surgeons with implants engineered to better match patient\nbone quality, including low, mid, and high bone-density implant options.\n\n“This fourth issued DEXA Technology patent represents another important\nmilestone in Aurora Spine’s strategy to protect and expand our leadership in\nbone density-matched spinal implant innovation,” said Trent J. Northcutt,\nPresident and CEO of Aurora Spine. “DEXA Technology was created to address a\nreal clinical challenge: patients do not all have the same bone quality. By\ngiving surgeons implant options designed around bone density, we believe\nAurora is advancing a more personalized and intelligent approach to spine\nsurgery. Through the issuance of this patent, Aurora’s competitive position\nwill improve and it support continued development of next-generation DEXA\nTechnology-based implants across the Company’s spinal implant portfolio.”\n\nAurora’s DEXA Technology platform was developed to improve the relationship\nbetween implant structure and patient bone quality. By offering implants with\ndensity-matched characteristics, Aurora aims to help surgeons select devices\nthat may better align with the mechanical environment of each patient’s\nanatomy.\n\n“This patent further validates years of research and development focused on\nmatching implant architecture to patient bone density,” said Laszlo\nGaramszegi, Chief Technology Officer of Aurora Spine. “The invention\nprotects important methods for using bone density information to guide implant\nselection, which is central to our DEXA platform. We believe this approach has\nthe potential to support better load sharing, reduce implant-related\ncomplications associated with poor bone quality, and help surgeons make more\ninformed intraoperative decisions.”\n\nAbout Aurora Spine\n\nAurora Spine Corporation (TSX Venture: ASG | OTCQB: ASAPF) is\nan innovative designer and manufacturer of minimally invasive spinal implants\nand interventional pain management technologies. Headquartered in Carlsbad,\nCalifornia, the company’s mission is to improve spinal surgery outcomes\nthrough simplified, integrated, and cost-effective solutions that advance\npatient care worldwide. Additional information can be accessed at\nwww.aurora-spine.com.\n\nNeither TSX Venture Exchange nor its Regulation Services Provider (as that\nterm is defined in the policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements, including statements\nregarding the potential benefits of Aurora Spine’s DEXA Technology, future\nproduct development, intellectual property strategy, commercialization plans,\nand potential clinical or surgical advantages. Forward-looking statements are\nbased on current expectations and assumptions and are subject to risks and\nuncertainties that could cause actual results to differ materially. Aurora\nSpine undertakes no obligation to update forward-looking statements except as\nrequired by applicable law.\n\nCompany and Investor Contacts\n\nAurora Spine Corporation\nTrent J. Northcutt\nPresident and Chief Executive Officer\nPhone: (760) 424-2004\n\nChad Clouse\nChief Financial Officer\nPhone: (760) 424-2004\n\nInvestor Relations\nAdam Lowensteiner\nLytham Partners\nPhone: (646) 829-9702\nEmail: asapf@lythampartners.com\n\nWebsite: www.aurora-spine.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/af1a0a7b-b883-41f9-8c86-a89bad3cc4a4)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3T6lCv","title":"Aurora Spine Announces Issuance of Fourth U.S. Patent Covering DEXA Technology® Bone Density-Matched Implants","author":"Globe Newswire","ticker":"ASG","created":"2026-05-07T11:15:00.111Z","tickers":["ASG"],"exchange":"","article_body":"CARLSBAD, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aurora Spine Corporation\n(“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader\nin the development of groundbreaking medical devices for spinal surgery, today\nannounced the issuance of its fourth U.S. patent related to Aurora’s\nproprietary DEXA Technology® platform.\n\nThe newly issued patent, U.S. Patent No. 12,605,252 B2, titled “Bone Density\nScan Result-Matched Orthopedic Implants and Methods of Use,” was issued on\nApril 21, 2026, and further strengthens Aurora Spine’s intellectual property\nportfolio surrounding patient-specific, bone density-matched implant selection\nand use.\n\nThe patented technology describes methods for obtaining a patient’s bone\ndensity information, including a DEXA T-score or bone density measurement,\nselecting an implant having a density level matched to the patient’s native\nbone at the implantation site, and implanting the selected device. The patent\nfurther supports Aurora’s broader DEXA Technology platform, which is\ndesigned to provide surgeons with implants engineered to better match patient\nbone quality, including low, mid, and high bone-density implant options.\n\n“This fourth issued DEXA Technology patent represents another important\nmilestone in Aurora Spine’s strategy to protect and expand our leadership in\nbone density-matched spinal implant innovation,” said Trent J. Northcutt,\nPresident and CEO of Aurora Spine. “DEXA Technology was created to address a\nreal clinical challenge: patients do not all have the same bone quality. By\ngiving surgeons implant options designed around bone density, we believe\nAurora is advancing a more personalized and intelligent approach to spine\nsurgery. Through the issuance of this patent, Aurora’s competitive position\nwill improve and it support continued development of next-generation DEXA\nTechnology-based implants across the Company’s spinal implant portfolio.”\n\nAurora’s DEXA Technology platform was developed to improve the relationship\nbetween implant structure and patient bone quality. By offering implants with\ndensity-matched characteristics, Aurora aims to help surgeons select devices\nthat may better align with the mechanical environment of each patient’s\nanatomy.\n\n“This patent further validates years of research and development focused on\nmatching implant architecture to patient bone density,” said Laszlo\nGaramszegi, Chief Technology Officer of Aurora Spine. “The invention\nprotects important methods for using bone density information to guide implant\nselection, which is central to our DEXA platform. We believe this approach has\nthe potential to support better load sharing, reduce implant-related\ncomplications associated with poor bone quality, and help surgeons make more\ninformed intraoperative decisions.”\n\nAbout Aurora Spine\n\nAurora Spine Corporation (TSX Venture: ASG | OTCQB: ASAPF) is\nan innovative designer and manufacturer of minimally invasive spinal implants\nand interventional pain management technologies. Headquartered in Carlsbad,\nCalifornia, the company’s mission is to improve spinal surgery outcomes\nthrough simplified, integrated, and cost-effective solutions that advance\npatient care worldwide. Additional information can be accessed at\nwww.aurora-spine.com.\n\nNeither TSX Venture Exchange nor its Regulation Services Provider (as that\nterm is defined in the policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements, including statements\nregarding the potential benefits of Aurora Spine’s DEXA Technology, future\nproduct development, intellectual property strategy, commercialization plans,\nand potential clinical or surgical advantages. Forward-looking statements are\nbased on current expectations and assumptions and are subject to risks and\nuncertainties that could cause actual results to differ materially. Aurora\nSpine undertakes no obligation to update forward-looking statements except as\nrequired by applicable law.\n\nCompany and Investor Contacts\n\nAurora Spine Corporation\nTrent J. Northcutt\nPresident and Chief Executive Officer\nPhone: (760) 424-2004\n\nChad Clouse\nChief Financial Officer\nPhone: (760) 424-2004\n\nInvestor Relations\nAdam Lowensteiner\nLytham Partners\nPhone: (646) 829-9702\nEmail: asapf@lythampartners.com\n\nWebsite: www.aurora-spine.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/af1a0a7b-b883-41f9-8c86-a89bad3cc4a4)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-07T11:15:00.162566863Z","server_sent_at_ms":1778152500162},"received_at":"2026-05-07T11:15:00.262Z","source_url":null},"analysis":{"id":"19825","press_release_id":"25290","analysis_json":{"industry":{"label":"Health Care Equipment & Services","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Aurora Spine announced the issuance of its fourth U.S. patent covering its DEXA Technology platform for bone density-matched spinal implants.\n\nThe newly issued patent, U.S. Patent No. 12,605,252 B2, covers methods for selecting implants based on a patient's bone density information, specifically the DEXA T-score.\n\nManagement stated the patent reinforces the company's competitive position and intellectual property portfolio supporting its minimally invasive solutions.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine IP expansion; low market impact expected."},"keyFigures":{},"quotedText":"This fourth issued DEXA Technology patent represents another important milestone in Aurora Spine’s strategy to protect and expand our leadership in bone density-matched spinal implant innovation","namedEntities":{"people":[{"name":"Trent J. Northcutt","role":"President and CEO"},{"name":"Laszlo Garamszegi","role":"Chief Technology Officer"},{"name":"Chad Clouse","role":"Chief Financial Officer"},{"name":"Adam Lowensteiner","role":"Investor Relations"}],"products":["DEXA Technology®"],"companies":[{"name":"Aurora Spine Corporation","ticker":"ASG"},{"name":"Lytham Partners","relationship":"investor relations"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Issuance of a patent strengthens the IP portfolio but does not immediately change revenue prospects or clinical status. This is a routine operational update for a small-cap medical device company."},"tickerRelevance":{"others":[],"primary":"ASG"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"patent_announcement","sectorWeight":"health_care"}},"event_type":"other","event_type_secondary":null,"sentiment":"bullish","material_impact_score":1,"narrative":"Aurora Spine announced the issuance of its fourth U.S. patent covering its DEXA Technology platform for bone density-matched spinal implants.\n\nThe newly issued patent, U.S. Patent No. 12,605,252 B2, covers methods for selecting implants based on a patient's bone density information, specifically the DEXA T-score.\n\nManagement stated the patent reinforces the company's competitive position and intellectual property portfolio supporting its minimally invasive solutions.","key_figures":{},"named_entities":{"people":[{"name":"Trent J. Northcutt","role":"President and CEO"},{"name":"Laszlo Garamszegi","role":"Chief Technology Officer"},{"name":"Chad Clouse","role":"Chief Financial Officer"},{"name":"Adam Lowensteiner","role":"Investor Relations"}],"products":["DEXA Technology®"],"companies":[{"name":"Aurora Spine Corporation","ticker":"ASG"},{"name":"Lytham Partners","relationship":"investor relations"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:6c7fa2f5e3b62e83","schema_hash":"sha256:ee8f711bc9bfba0d","created_at":"2026-05-07T20:57:46.564Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"patent_announcement","sectorWeight":"health_care"}},"durationMs":null,"modelName":"glm-4.7"}}